Premium
Modified natural and synthetically reconstituted surfactant therapies for acute lung injury caused by endotoxin in rats
Author(s) -
Tashiro K.,
Nishizuka K.,
Matsumoto Y.,
Ohta K.,
Suzuki Y,
Kobayashi T.
Publication year - 1999
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1034/j.1399-6576.1999.430807.x
Subject(s) - pulmonary surfactant , medicine , acute respiratory distress , lung , respiratory distress , neonatal respiratory distress syndrome , anesthesia , surfactant therapy , acute injury , pharmacology , surgery , biochemistry , chemistry , biology , pregnancy , genetics , gestational age
Background: Impairment of surfactant is involved in development of acute respiratory distress syndrome. To develop artificial surfactant substitute for clinical use, we prepared synthetically reconstituted surfactant (SRS) by adding porcine surfactant‐associated protein B and C (SP‐B and SP‐C) to synthetic phospholipids, and compared its effect with that of modified natural surfactant (MNS) in rats with acute lung injury caused by endotoxin. Methods: Escherichia coli endotoxin (71±18 mg · kg −1 , mean±SD) was injected into the tracheas of 27 anesthetized and mechanically ventilated rats (F I O 2 of 1.0). When the PaO 2 had decreased to below 26.7 kPa, the rats were randomly assigned to three groups. The MNS and SRS groups (n=9, each) were given 100 mg · kg −1 of MNS and SRS through the airway, respectively. The control group (n=9) was given air in the same volume. Results: The PaO 2 of the control group remained below 13.3 kPa until the end of the experiment (6 h after the assignment). The PaO 2 of the MNS group increased to 45.3±9.5 kPa and that of the SRS group to 45.5±3.7 kPa 0.5 h after the assignment ( P <0.05 vs. control group). The PaO 2 of both groups remained above 40 kPa throughout the experiment. Conclusion: In this acute lung injury model, the effects of replacement therapy with surfactant consisting of synthetic phospholipids, SP‐B and SP‐C, were the same as those observed with MNS. These results warrant development of surfactant substitutes based on natural SP‐B and SP‐C, and synthetic phospholipids.